REGENXBIO (RGNX) - 48.12% Below 52-Week High: Buy or Wait?

Stock Details

REGENXBIO Inc. (RGNX), a prominent company in the healthcare sector within the biotechnology industry, is based in United States and primarily trades on the NMS.Currently, the stock is trading at $8.40. Over the past 52 weeks, it has ranged between $6.89 and $16.19. This places the current price at 51.9% of its 52-week high and 21.9% above its 52-week low. Recent trading volume was recorded at 59,323. The 14-day Relative Strength Index (RSI) stands at 46.11, suggesting neutral conditions. The stock is currently trading below its 50-day moving average of $8.72 by 3.67%. Similarly, it is below its 200-day moving average of $10.53 by 20.23%. The MACD histogram is -0.03, indicating bearish momentum (MACD Line: 0.01, Signal Line: 0.04).

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

N/A

Forward P/E

-3.96

Price to Book

4.30

EV/EBITDA

-3.29

EPS (TTM)

-$3.76

Price to Sales

2.63

Beta

1.13

Similar volatility to market

Q:How is RGNX valued relative to its earnings and growth?

Valuation data is not available for this stock.

Q:What is RGNX's risk profile compared to the market?

With a beta of 1.13, REGENXBIO Inc. is roughly as volatile as the market, moving in line with broad market trends. This moderate beta suggests the stock offers market-level returns without excessive volatility. The price-to-book ratio of 4.30 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

-113.75%

Operating Margin

-189.99%

EBITDA

$-145,583,008

Return on Equity

-107.00%

Return on Assets

-21.93%

Revenue Growth (YoY)

43.00%

Q:How profitable and efficient is RGNX's business model?

REGENXBIO Inc. achieves a profit margin of -113.75%, meaning it retains $-113.75 from every $100 in revenue after all expenses. This relatively low margin suggests the company operates in a competitive environment or high-cost industry where profitability is challenging. The operating margin of -189.99% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at -107.00% and ROA at -21.93%, the company achieves moderate returns on invested capital.

Q:What are RGNX's recent growth trends?

REGENXBIO Inc.'s revenue grew by 43.00% year-over-year, representing robust expansion that significantly outpaces typical market growth rates. This strong top-line performance suggests the company is successfully capturing market share or benefiting from favorable industry trends. These growth metrics should be evaluated against Biotechnology industry averages for proper context.

Company Size & Market

Market Cap

$448.6M

Revenue (TTM)

$170.44M

Revenue/Share (TTM)

$3.31

Shares Outstanding

51.62M

Book Value/Share

$2.02

Asset Type

EQUITY

Q:What is RGNX's market capitalization and position?

REGENXBIO Inc. has a market capitalization of $448.6M, classifying it as a small-cap stock (under $2B). Small-caps offer significant growth potential but come with higher volatility and risk. They can be more sensitive to economic conditions but may provide outsized returns if successful. With 51.62M shares outstanding, the company's ownership is relatively concentrated. As a participant in the Biotechnology industry, it competes with other firms in this sector.

Q:How does RGNX's price compare to its book value?

REGENXBIO Inc.'s book value per share is $2.02, while the current stock price is $8.40, resulting in a price-to-book (P/B) ratio of 4.16. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As EQUITY, this represents a specific type of security.

Analyst Ratings

Analyst Target Price

$27.82

231.17% upside potential

Analyst Recommendations

Strong Buy

Buy

Hold

Sell

Strong Sell

Q:How reliable are analyst predictions for RGNX?

11 analysts cover RGNX with 91% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $27.82 implies 231.2% upside, but targets are often adjusted to follow price moves rather than predict them.

Q:What is the Wall Street consensus on RGNX?

Current analyst recommendations:4 Strong Buy, 6 Buy, 1 Hold, 00The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Apr 29, 2026, 02:20 AM

Technical Indicators

RSI (14-day)

46.11

Neutral

50-Day Moving Average

$8.72

-3.67% below MA-50

200-Day Moving Average

$10.53

-20.23% below MA-200

MACD Line

0.01

MACD Signal

0.04

MACD Histogram

-0.03

Bearish

Q:What does RGNX's RSI value tell investors?

The RSI (Relative Strength Index) for RGNX is currently 46.11, indicating the stock is in neutral territory (40-60 range). Neither buyers nor sellers have clear control, suggesting consolidation or balanced market forces. Combined with the price being below the 50-day moving average, this confirms bearish conditions.

Q:How should traders interpret RGNX's MACD and moving average crossovers?

MACD analysis shows the MACD line at 0.01 below the signal line at 0.04, with histogram at -0.03. This bearish crossover indicates downward pressure. The narrow histogram suggests a potential trend change ahead. The 50-day MA ($8.72) is below the 200-day MA ($10.53), forming a death cross pattern that often warns of extended weakness. Price is currently below both MAs, confirming weakness.

Indicators last updated: Apr 29, 2026, 11:09 AM

REGENXBIO Inc. (RGNX) Stock